Entrada Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| TRDA | ENTA | RLMD | KROS | CTNM | CADL | |
|---|---|---|---|---|---|---|
| Market cap | 214.15M | 358.24M | 374.41M | 230.19M | 322.22M | 748.35M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -1.8 | -5.2 | -8.6 | -1.8 | -4.5 | -15.6 |
| Price/book | 0.8 | 3.5 | 1.8 | 0.9 | 1.3 | 5.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −2.41% | +8.79% | +67.82% | −24.80% | +12.15% | +53.63% |
| Today | −3.00% | −1.60% | +3.54% | −2.85% | −35.99% | −1.61% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All TRDA news ›Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity
Entrada Therapeutics (ENTR) Buy call: $8.50 fair value (~52% upside). Valuation is anchored by risk-adjusted pipeline estimates. See more details here. - Entrada Therapeutics is rated Buy with a $8.50 fair value, offering ~52% upside from…
Comparing Black Diamond Therapeutics (NASDAQ:BDTX) & Entrada Therapeutics (NASDAQ:TRDA)
Posted by Michael Walen on Oct 11th, 2026 Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) and Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
defenseworld.net1
-
seekingalpha.com1
-
themarketsdaily.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.